Company news
Arbutus Biopharma Corporation news in 2026
Arbutus Biopharma Corporation's news releases, calls and decks from 2026, newest first.
Arbutus Announces Final Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
October 1, 2026
Arbutus Announces Preliminary Results of Its US$230 Million Modified “Dutch Auction” Tender Offer
September 30, 2026
Arbutus Biopharma Commences US$230 Million Modified “Dutch Auction” Tender Offer of its Common Shares at a Price Not Greater Than US$5.75 Nor Less Than US$5.00 Per Share
August 24, 2026
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
August 21, 2026
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 12, 2026
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
July 16, 2026
Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 13, 2026
Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
April 14, 2026
Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update
March 22, 2026
Genevant Sciences and Arbutus Biopharma Announce $2.25 Billion Global Settlement With Moderna
March 3, 2026